Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has been given an average rating of “Buy” by the thirteen ratings firms that are currently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $71.60.
Several equities research analysts have weighed in on the stock. Barclays restated a “hold” rating and issued a $55.00 target price on shares of Biohaven Pharmaceutical in a research note on Friday, May 31st. Zacks Investment Research downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, July 19th. ValuEngine cut shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a report on Wednesday, June 19th. Goldman Sachs Group set a $89.00 price objective on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a report on Wednesday. Finally, Oppenheimer set a $68.00 target price on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, June 19th.
In other news, Director John W. Childs purchased 10,000 shares of the stock in a transaction dated Wednesday, June 26th. The stock was acquired at an average cost of $40.37 per share, for a total transaction of $403,700.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vlad Coric bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The stock was bought at an average cost of $40.22 per share, for a total transaction of $201,100.00. The disclosure for this purchase can be found here. Insiders bought a total of 22,500 shares of company stock valued at $900,675 in the last quarter. Insiders own 23.90% of the company’s stock.
Biohaven Pharmaceutical stock traded up $0.59 during midday trading on Thursday, reaching $41.49. The stock had a trading volume of 561,501 shares, compared to its average volume of 588,713. Biohaven Pharmaceutical has a 52-week low of $29.17 and a 52-week high of $67.86. The company has a fifty day moving average of $40.46 and a 200 day moving average of $49.77.
Biohaven Pharmaceutical (NYSE:BHVN) last issued its earnings results on Thursday, August 8th. The company reported ($2.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.09) by ($0.26). Research analysts anticipate that Biohaven Pharmaceutical will post -7.51 earnings per share for the current fiscal year.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Further Reading: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.